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 Patient: Male, 71-year-old
 Final Diagnosis: Castration-resistant prostate cancer
 Symptoms: None
 Medication: —
 Clinical Procedure: Chemotherapy
 Specialty: Urology
 Objective: Unusual clinical course
 Background: Cabazitaxel is a second-generation taxane approved for patients with metastatic castration-resistant prostate 
cancer (CRPC). Although cabazitaxel improves overall survival when used following docetaxel chemotherapy, 
duration of the clinical response is relatively short, and few patients achieve a long-term response.
 Case Report: A 71-year-old man with prostate adenocarcinoma with an initial prostate-specific antigen (PSA) level of 4956 
ng/ml, Gleason score 4+5 and cTxN0M1b was referred to our department for treatment. Several therapeu-
tic approaches, including androgen deprivation therapy, with a combination of bicalutamide and a luteinizing 
hormone-releasing hormone analogue, and 4 sequential hormonal therapies including flutamide, estramus-
tine, enzalutamide, and abiraterone, all failed to prevent disease progression. Subsequently, after 5 cycles of 
docetaxel chemotherapy were also ineffective, cabazitaxel chemotherapy at a dose of 20 mg/m2 together with 
prednisone and pegfilgrastim was initiated. The patient developed grade 4 thrombocytopenia during the first 
4 cycles, and the dosage of cabazitaxel had to be tapered to 12.5 mg/m2 by the fifth cycle. In subsequent cy-
cles, the treatment was continued without grade 4 thrombocytopenia or any other toxicities ³grade 3. The pa-
tient achieved a long-term clinical response over 4 years and his PSA level continued to decrease, from 29.8 
ng/ml at treatment initiation to a nadir of 2.0 ng/ml after the 60th cycle.
 Conclusions: The present case is a rare example of a sustained response to low-dose cabazitaxel, and suggests its potential 
as a treatment option for metastatic CRPC patients. In our patient, this approach achieved a good clinical re-
sponse with manageable toxicity over the long term.
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Background
Prostate cancer is the most common malignancy in men, with 
an estimated 174 650 new cases and 31 620 deaths in the 
United States in 2019 [1]. Currently, 10-20% of patients de-
velop castration-resistant prostate cancer (CRPC) within 5 
years of starting androgen deprivation therapy [2]. CRPC has 
a poor prognosis and patients have an impaired quality of life. 
Depending on the extent of disease progression and severity 
of symptoms, life expectancy from the time of the develop-
ment of castration resistance is 9-36 months [3]. Over the last 
decade, docetaxel-based chemotherapy has become the main-
stay option for the treatment of CRPC. More recently, sever-
al new therapeutic agents have been approved, including the 
androgen signaling inhibitors enzalutamide and abiraterone, 
the radionuclide radium-223, and the new taxane cabazitaxel.
The latter is a novel semisynthetic anti-microtubule agent 
derived from taxanes, approved by the U.S. Food and Drug 
Administration (FDA) for use as second-line chemotherapy af-
ter docetaxel for metastatic CRPC, based on the results of the 
phase 3 TROPIC study [4]. In that study, cabazitaxel significant-
ly increased the prostate-specific antigen (PSA) response rate 
and improved overall survival (OS) by 2.4 months (15.1 vs 12.7 
months, P<0.0001) compared with mitoxantrone [4]. In Japan, 
cabazitaxel was approved in 2014 following a phase 1 study, 
which documented that its pharmacokinetics and safety pro-
file in Japanese patients was consistent with previous studies 
in other populations [5,6]. The introduction of cabazitaxel into 
clinical practice was expected to provide clinical benefit inde-
pendent of any prior treatment regimens including androgen 
receptor targeted therapies or docetaxel [7,8]. However, caba-
zitaxel treatment-related toxicity is a major limitation for de-
livering an effective dose to some patients, and this can lead 
to a negative impact on clinical outcomes. Furthermore, al-
though a beneficial effect on survival from extending the peri-
od of cabazitaxel treatment has been suggested, the duration 
of response is relatively short. Only a few patients have thus 
far been reported to have achieved long-term responses. Here, 
we report an unusual clinical case of metastatic CRPC in which 
a long-term clinical response to cabazitaxel was achieved, be-
yond 60 cycles, using a dose reduced to 12.5 mg/m2 to man-
age severe thrombocytopenia.
Case Report
A 71-year-old man was referred to our department for the 
treatment of metastatic prostate cancer. He had been diag-
nosed with prostate cancer (initial PSA level of 4956 ng/ml, 
Gleason score 4+5, cTxN0M1b) at another institution 1 year 
before. Bone imaging revealed multiple metastases (Figure 1A), 
although no nodal or visceral metastasis was observed by 
computed tomography at the time of diagnosis. The patient 
was treated with a combination of bicalutamide and a lutein-
izing hormone-releasing hormone (LH-RH) analogue, but de-
veloped CRPC after 30 months. Over the next 5 years, he re-
ceived 4 hormonal therapies, including flutamide, estramustine, 
enzalutamide, and abiraterone, but his PSA level continued to 
increase. Docetaxel chemotherapy was initiated at a dose of 
70 mg/m2 intravenously every 3 weeks together with a bone-
modifying agent, denosumab (120 mg) every 4 weeks. This 
treatment was well tolerated, but the PSA level continued to 
rise, from 8.3 ng/ml at the beginning of treatment to 29.8 ng/
ml after 5 cycles of docetaxel therapy. At the age of 78 years, 
the patient was started on cabazitaxel beginning with 20 mg/
m2 every 3 weeks together with prednisone and pegfilgras-
tim. During the first cycle, grade 3 neutropenia and grade 4 
thrombocytopenia occurred (graded according to the Common 
Terminology Criteria for Adverse Events [CTCAE] version 4.0 [9]). 
Therefore, cabazitaxel was reduced to 17.5 mg/m2 in the sec-
ond and third cycles, with grade ³3 neutropenia no longer oc-
curring, but grade 4 thrombocytopenia still present. Thus, for 
the third cycle, platelet transfusion was performed with plate-
let counts of 12 000/µl. For the fourth cycle, the dose of ca-
bazitaxel was reduced to 15 mg/m2, but platelet transfusion 
was still required to compensate for the grade 4 thrombocy-
topenia. After the fourth cycle, the PSA level decreased to 9.9 
ng/ml and there was no radiological progression. The patient 
had no symptoms of non-hematological toxicity due to che-
motherapy. Hence, we decided to reduce the dose of cabazi-
taxel and continue until progression, with the fifth cycle using 
a dose of 12.5 mg/m2. In the subsequent cycles, the treatment 
was continued, and there was no recurrence of grade 4 throm-
bocytopenia or any other toxicities ³grade 3. There was a de-
layed platelet recovery at the 18th cycle, and treatment was 
continued every 4 weeks at the same dose from the 19th cy-
cle. Bone scintigraphy showed the occurrence of jaw osteo-
necrosis after the 26th cycle, so denosumab was discontin-
ued until treatment for this was complete (Figure 1B). After 
the 52nd cycle, abnormal uptake was seen in the right femoral 
head and right sixth rib (Figure 1C). Further examination by 
MRI revealed idiopathic femoral head necrosis and traumat-
ic rib injury without any findings of metastatic bone tumors. 
Nonetheless, cabazitaxel therapy was continued without evi-
dence of radiological progression, and the PSA level gradually 
decreased to a nadir at 2.0 ng/ml at the end of the 60th cycle 
(Figure 2). Fifty-four months from the initiation of cabazitax-
el, the patient continues to receive cabazitaxel therapy with 
uneventful adverse effects.
Discussion
Based on the results of the TROPIC trial demonstrating that 25 
mg/m2 of cabazitaxel improved OS, this drug is now widely used 
Kubota S. et al: 
PSA after cabitaxel for castration-resistant prostate cancer
© Am J Case Rep, 2021; 22: e930989
e930989-2 Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)][Web of Science by Clarivate]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
for metastatic CRPC after failure of treatment with docetax-
el [4]. However, severe adverse events (AEs) are frequently re-
ported, and some patients must discontinue chemotherapy or 
experience decreased activities of daily living on continuation. 
Subsequently, the PROCELICA trial determined the non-inferiority 
for OS of a reduced-dose cabazitaxel regimen (20 mg/m2 rath-
er than the standard 25 mg/m2), which resulted in an improved 
safety profile [4]. On this basis, the U.S. FDA approved 20 mg/m2 
of cabazitaxel as the recommended initial dosage with addition-
al dose reduction to 15 mg/m2 for the management of AEs [10].
In the present case, the starting dose of cabazitaxel was set at 
20 mg/m2 because of the patient’s age and history of heavy pre-
treatment for CRPC, but further dose reduction was required 
due to severe thrombocytopenia. Even with dose reduction to 
15 mg/m2, grade 4 thrombocytopenia still occurred, and so the 
dose of cabazitaxel was further reduced to 12.5 mg/m2. This 
finally resulted in thrombocytopenia becoming manageable. 
The frequency of thrombocytopenia ³grade 3 on cabazitaxel 
chemotherapy is reported as 4-6.8% [4,6,11,12]. In Japanese 
patients in a real-world setting, this was the third most com-
mon reason leading to discontinuation or dose reduction fol-
lowing neutropenia [12]. These AEs associated with myelo-
suppression, including neutropenia and thrombocytopenia, 
can be managed by additional dose reduction [11]. However, 
no information on the oncological outcome of cabazitaxel at a 
dose of <20 mg/m2 had been reported. Previously, outcomes, 
including the rate and duration of the PSA response, on a re-
duced-dose regimen were reported to be worse than on a 
standard-dose regimen [11,12]. Despite the possibility that, as 
mentioned above, the therapeutic effect might be reduced at 
a lower dose, we were concerned about the risk of recurrence 
Figure 1.  Status of bone metastasis by scintigraphy. (A) Multiple metastases to ribs, vertebrae and pelvic bone at the time of 
prostate cancer diagnosis. (B) Jaw osteonecrosis (black arrowhead) induced by denosumab occurring after the 26th cycle of 
cabazitaxel. (C) Abnormal uptake in the right femoral head (white arrowhead) and right sixth rib (black arrow) caused by 
idiopathic femoral head necrosis and traumatic rib injury after the 52nd cycle of cabazitaxel.
A B C
Kubota S. et al: 
PSA after cabitaxel for castration-resistant prostate cancer
© Am J Case Rep, 2021; 22: e930989
e930989-3 Indexed in: [PMC] [PubMed] [Emerging Sources Citation Index (ESCI)][Web of Science by Clarivate]
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
and rapid tumor regrowth if we discontinued cabazitaxel al-
together [13]. We therefore decided to continue cabazitaxel 
treatment with an additional dose reduction.
Surprisingly, the PSA level in the present case continued to 
decrease despite reducing the relative dose intensity of ca-
bazitaxel to less than 50%, reaching a nadir at the 60th cy-
cle; thus, there was a 93.3% PSA reduction from baseline at 
51 months. Furthermore, during the cabazitaxel treatment, 
no symptoms due to non-hematological AEs or disease pro-
gression were observed. Previously, some cases responding 
to ³20 mg/m2 of cabazitaxel beyond 20 cycles have been re-
ported [14-16], but none had been continued beyond 30 cy-
cles due to toxicities or disease progression. To the best of our 
knowledge, the present patient is the first reported to have 
achieved a long-term response beyond 30 cycles despite re-
ceiving a dose of <20 mg/m2. Although the mechanisms re-
sponsible for the long-term response and severe thrombocy-
topenia in our patient are unknown, the pharmacokinetics of 
cabazitaxel may be relevant. Cabazitaxel is a substrate of the 
transmembrane transporters P-glycoprotein (encoded by the 
gene ABCB1), OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) 
and is mainly metabolized by isoenzymes CYP3A4/5 and to a 
lesser extent by CYP2C8 in the liver [17-19]. Some single-nu-
cleotide polymorphisms in these genes are known to affect 
the pharmacokinetics of cabazitaxel and are associated with 
Figure 2.  Clinical course after initiation of cabazitaxel chemotherapy. LH-RH – luteinizing hormone-releasing hormone; 
CBZ – cabazitaxel; PSA – prostate-specific antigen.
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the incidence of grade 3-4 toxicity, although their impact on 
therapeutic efficacy for CRPC has not been established [19]. In 
the present case, no drugs affecting the pharmacokinetics of 
cabazitaxel, such as inhibitors of CYP3A or OATP1B, were ad-
ministered during treatment. Although pharmacokinetic stud-
ies were not undertaken in the present case, we anticipate 
that further studies will elucidate the mechanisms underlying 
interpatient variability of efficacy and toxicity of cabazitaxel.
Conclusions
The present case showed long-term clinical benefits from ex-
tended cabazitaxel therapy at a very low dose without severe 
toxicity or impaired quality of life. Severe AEs are a serious 
problem that commonly interferes with the continuation of 
cabazitaxel therapy, but can be managed by dose reduction.
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